secwatch.observer — SEC 8-K summary
======================================

Issuer:     PETMED EXPRESS INC (PETS)
CIK:        0001040130
Form:       8-K
Filed at:   2026-11-10T21:17:45+00:00
Accession:  0001040130-26-000068
Event type: earnings
Sentiment:  negative
Materiality: 0.62
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

PetMeds Q2 net sales fall 19.4% to $35.8M; net loss narrows to $6.4M ($0.31/sh)
-------------------------------------------------------------------------------

- Net sales of $35.8M vs $44.4M a year ago, down 19.4%, driven by lower prescription medication sales and higher consumer promotional usage.
- Net loss of $6.4M, or $(0.31) per diluted share, versus a net loss of $8.5M, or $(0.41) per diluted share, in the prior-year quarter.
- Adjusted EBITDA was $(3.6)M, worse than $(2.3)M a year ago; lower G&A and advertising spend was offset by weaker gross profit and lower manufacturer rebates.
- CEO Jeff Willard said operations are "stabilized"; customer acquisition cost fell 32% YoY, with focus on repositioning the brand and improving retention.
- No financial guidance was provided in the release; earnings webcast scheduled for 4:30pm Eastern on November 10, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1040130/000104013026000068/0001040130-26-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1040130/000104013026000068/pets-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001040130-26-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer